Rep. Brian Mast, a leading Republican advocate for cannabis reform on Capitol Hill, has proposed that ongoing federal rescheduling efforts should not stop at marijuana. Instead, he advocates for a comprehensive, across-the-board review of all federally controlled substances.

During a recent discussion, the Florida lawmaker stated his support for evaluating cannabis, hemp, psilocybin, tranquilizers, and other restricted compounds simultaneously. This broad review signals a potential shift in how federal lawmakers approach drug policy—moving away from isolated scheduling updates toward a systemic overhaul. For the broader botanical and wellness industries, this positioning connects the future of cannabis reform directly to the wider debate surrounding psychedelic medicine and alternative therapeutics.

While cannabis rescheduling currently dominates industry attention, widening the scope to include psilocybin and hemp points toward a vastly different regulatory environment on the horizon. Dispensary owners and brand operators must monitor how legislative momentum around cannabis intersects with emerging research and policy changes for adjacent compounds. If adopted, a comprehensive reevaluation of federal schedules could drastically alter compliance frameworks, product development pipelines, and retail strategies across multiple regulated sectors.

For now, the commentary highlights growing bipartisan interest in modernizing outdated drug classifications, creating potential new commercial horizons for businesses positioned at the intersection of cannabis, hemp, and functional wellness.